An interventional study of CAPA-IVM in Infertility, In Vitro Maturation of Oocytes and Assisted Reproduction Technologies, sponsored by Inception Fertility Research Institute, LLC. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Inception Fertility Research Institute, LLC · Not applicable, Interventional, and Treatment
A study to assess the Capacitation - in-vitro maturation (CAPA-IVM) system as an option for patients with a good ovarian reserve to achieve pregnancy.
CAPA-IVM is being evaluated for its feasibility as an In vitro maturation (IVM) system in US fertility clinics. IVM is a laboratory process for maturing immature oocytes (eggs) outside of the body after egg retrieval. Egg retrievals are performed without prior ovarian stimulation.
2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.
This study's planned enrollment of 40 is below the median of 135 across 1,412 interventional studies indexed under Infertility.
Browse Infertility studies →Inception Fertility Research Institute, LLC is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo egg retrieval prior to in vitro maturation with CAPA-IVM system and subsequent frozen embryo transfer.
Device: CAPA-IVM
CAPA-IVM is a two-step IVM process to mature oocytes in the laboratory after egg retrieval.
Metaphase II rate
The metaphase II (MII) rate is defined as the number of oocytes that reach MII stage of development divided by the number of cumulus-oocyte-complexes (COCs) placed into CAPA-IVM culture.
Time frame: Assessed approximately 40 hours after egg retrieval
Number of MII oocytes
The number of oocytes that reach the metaphase II (MII) stage of development after CAPA-IVM culture
Time frame: Assessed approximately 40 hours post egg retrieval
Fertilization rate
The fertilization rate is defined as the number of embryos that have 2 pro-nuclei post fertilization by intracytoplasmic sperm injection (ICSI)
Time frame: Assessed 16-18 hours post fertilization
Number of blastocysts
The number of embryos that make it to the blastocyst stage of development post fertilization
Time frame: Assessed 5-7 days post fertilization
Number of blastocysts vitrified
The number of embryos that are cryopreserved by vitrification post fertilization
Time frame: Assessed 5-7 days post fertilization
Number of blastocysts submitted for PGT-A
The number of embryos that are biopsied and samples sent for PGT-A testing
Time frame: Assessed 5-7 days post fertilization
Number of euploid blastocysts
Number of embryos that had a euploid result from PGT-A testing
Time frame: Assessed 2-4 weeks post embryo biopsy
Positive beta-hCG rate
The number of patients with a serum QHCG level greater than 5 after embryo transfer divided by the total number of embryo transfers
Time frame: Assessed 9-11 days post embryo transfer
Ongoing pregnancy rate
The number of patients who have an ongoing intrauterine pregnancy at the last study visit
Time frame: Assessed approximately 10 weeks post embryo transfer
Live birth rate
Number of patients who had a live birth after embryo transfer
Time frame: Assessed approximately 40 weeks post embryo transfer
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inception Fertility Research Institute, LLC →